Journal ArticleOPEN ACCESS

Xigduo: dapagliflozin plus metformin for T2DM

  • Chaplin S
  • McCourt C
  • Joseph F
Prescriber (2014) 25(19) 36-38
DOI: 10.1002/psb.1255
N/ACitations
Citations of this article
17Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Xigduo, a combination of dapagliflozin and metformin, is licensed as second‐line therapy in patients with type 2 diabetes. In our New products review, Steve Chaplin presents the data relating to its efficacy and adverse events and Drs Claire McCourt and Frank Joseph discuss its place in therapy.

Cite

CITATION STYLE

APA

Chaplin, S., McCourt, C., & Joseph, F. (2014). Xigduo: dapagliflozin plus metformin for T2DM. Prescriber, 25(19), 36–38. https://doi.org/10.1002/psb.1255

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free